Lectin Complement Protein Collectin 11 (CL-K1) and Susceptibility to Urinary Schistosomiasis

Justin S. Antony¹, Olusola Ojurongbe¹,², Peter G. Kremsner¹, Thirumalaisamy P. Velavan¹,³*

¹ Institute of Tropical Medicine, University of Tübingen, Tübingen, Germany, ² Ladoke Akintola University of Technology, Ogbomoso, Nigeria, ³ Fondation Congolaise pour la Recherche Medicale, Brazzaville, Republic of Congo

* velavan@medizin.uni-tuebingen.de

Abstract

Background

Urinary Schistosomiasis is a neglected tropical disease endemic in many sub-Saharan African countries. Collectin Kidney 1 (CL-K1, encoded by COLEC11 on chromosome 2p25.3), a member of the vertebrate C-type lectin super family, has recently been identified as a pattern-recognition molecule (PRR) of the lectin complement pathway. CL-K1 is preferentially expressed in the kidneys, but also in other organs and it is considered to play a role in host defense to some infectious agents. Schistosome teguments are fucosylated and CL-K1 has, through its collagen-like domain, a high binding affinity to fucose.

Methodology/Principal Findings

We utilized a Nigerian study group consisting of 167 Schistosoma haematobium infected individuals and 186 matched healthy subjects, and investigated the contribution of CL-K1 deficiency and of COLEC11 polymorphisms to infection phenotype. Higher CL-K1 serum levels were associated with decreased risk of schistosome infection ($P_{corr} = 0.0004$). CL-K1 serum levels were differentially distributed between the COLEC11 genotypes and haplotypes observed. The non-synonymous variant $p.R216H$ was associated with the occurrence of schistosomiasis (OR = 0.44, 95%CI = 0.22–0.72, $P_{corr} = 0.0004$). The reconstructed COLEC11*TCCA haplotypes were associated with higher CL-K1 serum levels ($P = 0.002$) and with decreased schistosomiasis (OR = 0.38, 95%CI = 0.23–0.63, $P_{corr} = 0.0001$).

Conclusions

In agreement with findings from our earlier published study, our findings support the observation that CL-K1 and their functional variants may be host factors associated with protection in schistosomiasis and may be a useful marker for further investigations.
Author Summary

Collectin Kidney 1 (CL-K1) was discovered in 2006. It is a pattern-recognition molecule (PRR) of the lectin complement pathway and is mainly expressed in the kidneys. We investigated a possible functional role of CL-K1 during urinary schistosomiasis on the basis of the rationale: i). Schistosome teguments are fucosylated and CL-K1 has high binding affinity to fucose ii). As CL-K1 is structurally similar to MBL, we hypothesize the involvement of CL-K1 in immune modulation during urinary schistosomiasis. We investigated the circulating CL-K1 serum levels in our study group. We initially screened the entire promoter and the exons of the COLEC11 gene for population specific variants. We validated four promoter variants and one non-synonymous substitution in exon8 for possible associations with urinary schistosomiasis and circulating CL-K1 serum levels. The study was conducted in Nigeria where the largest number of registered cases of schistosomiasis (29 million) for any sub-Saharan African country has been documented. Our findings support the observation that CL-K1 and functional variants are host factors that may be associated with protection in schistosomiasis and may be a useful marker for further investigations.

Introduction

Urogenital schistosomiasis, which is caused by infection with the trematode Schistosoma haematobium, is a major public health problem in sub-Saharan Africa (SSA). Of the more than 200 million cases reported worldwide, 93% occur in SSA [1]. Up to two-thirds of S. haematobium infections result in genital schistosomiasis [2]. The incidence of S. haematobium infections in SSA, however, is most likely underreported and might be much higher [3]. Schistosomiasis accounts for the loss of more than 70 million disability adjusted life years (DALYs) [4,5]. A large proportion of infected individuals experience hematuria (70 million), dysuria (32 million), bladder-wall pathology (18 million), and severe hydronephrosis (10 million) [6]. Urinary schistosomiasis is endemic in Nigeria and approximately 25 million people are currently infected, with an estimated 101 million at risk [7]. Schistosomiasis can also increase the risk of urinary tract infections and bladder cancer [8–10]. Children and early adolescents are at high risk of infection as their daily activities regularly include contact with water infested with infectious cercariae [11]. Limited access to praziquantel treatment for schistosomiasis, repeated re-exposure, and rapid reinfections all contribute to the disease burden [11,12].

Schistosomes are bisexual multicellular helminth parasites with six developmental stages including, adult worms, eggs, miracidia, sporocysts, cercariae and schistosomulae [13]. Schistosomes have an outer syncytial cytoplasmic layer, the tegument [14]. Previous studies have shown that the teguments consist of fucosylated carbohydrate epitopes (glycotopes) [15] and glycoproteins [16] which are expressed at all developmental stages. These glycoconjugates act as pathogen associated molecular patterns (PAMPs) that are recognized by pattern recognition molecules (PRMs) such as the C-type lectins [17]. Earlier in vitro studies have demonstrated successful complement-mediated tegument damage in the adult schistosomes [18]. We have previously shown that the lectin proteins mannose binding lectin (MBL) and MBL-associated serine protease 1 (MASP-1) and MASP-2 interact with schistosomal glycoconjugates, and subsequently activate the lectin complement cascade [19].

Collectin kidney 1 (CL-K1 also known as Collectin 11), is a member of the group of C-type lectins. The role of CL-K1 appears to be analogous to that of other C-type lectins [20]. To date, many studies have concentrated on the complement proteins MBL [21–24] and ficolins [25–28]
in disease. Far less is known about the mechanism of action of CL-K1. The human CL-K1 is en-
coded by COLEC11 (OMIM 612502) on chromosome 2 at position 2p25.3 [29]. CL-K1 is a cir-
culating serum protein and is expressed in many tissues. High mRNA expression is observed in
kidneys, liver and in the adrenal glands. Similar to MBL, CL-K1 has a collagen like domain and a
carbohydrate recognition domain (CRD) [20,30,31]. Six different genetic variants have been ob-
served in a homozygous state in individuals affected with the rare Carnevale, Mingarelli, Mal-
puech and Michels (also known as 3MC) syndrome [32]. Two affected individuals with the p.
Gly204Ser amino acid substitution in CRD of COLEC11 had undetectable amounts of CL-K1 in
their serum. Moreover, CL-K1 was shown to be a guidance cue for neural cell migration during
embryogenesis [32]. The COLEC11 variant rs10210631 is responsible for high IgE production in
children [33]. CL-K1 recognizes pathogens by interacting with parasites’ glycoconjugates
[20,30]. A recent study has shown that CL-K1 can also deposit C4b upon binding with mannan
in the presence of MASP-2 [34]. In addition, interactions of CL-K1 with MASP-1/3 have been
well demonstrated [20,30].

We investigated the functional role of CL-K1 during urinary schistosomiasis on the basis of
the following rationale: i). Schistosome teguments are fucosylated and CL-K1 has a high bind-
ing affinity to fucose [35] ii). as CL-K1 is structurally similar to MBL, we hypothesized that
CL-K1 might be involved in immune modulation during urinary schistosomiasis. We therefore
investigated CL-K1 serum levels in a study group of Nigerian individuals of Yoruba ethnicity
as described in our previous studies [36,37]. Furthermore, we screened the entire COLEC11
gene for population specific functional variants. We then evaluated four promoter variants and
one non-synonymous substitution in COLEC11 exon8 for associations with urinary schistoso-
miasis and circulating CL-K1 serum levels.

Materials and Methods

Ethics statement

Informed oral consent in the local language was obtained from all participants; for those who
were children, informed consent was obtained from respective parents and/or guardians. The
consent was verbal because the study was conducted in rural communities where the level of
literacy was low. If the participants could not read or write, verbal consent was obtained after
explaining the purpose of the study to them. The consent was written in a note book and only
consenting individuals were recorded. The procedure was approved by the ethical committee
of the Ladoke Akintola University of Technology, Ogbomoso, Nigeria. Only those who provid-
ed their consent were recruited in the study. Ethical approval was also obtained from the ethical
committee of Ministry of Health, Abeokuta Ogun State, Nigeria.

Study design

Two villages known to be endemic for S. haematobium, Ilewo Orile (Abeokuta North) and Ore
(Osogbo), were chosen for the study. The communities lack sufficient clean water supply, safe
waste disposal and essential health centers. Members of the communities depend on rivers in
close proximity for their daily needs (collecting water, washing clothes, bathing). Fishing and
petty trading are the most common occupations. Based on responses to a questionnaire, over
93% of the participants had regular water contact (defined as at least four contacts to the in-
fected river in a week) for their daily needs. Most of the study participants had similar frequen-
cies of exposure with water infested with infectious cercariae. Epidemiological studies of
urinary schistosomiasis in Ogun state, Nigeria reported an infection rate of more than 80%
[38]. The current study is a cross-sectional study and individuals were recruited blindly irre-
spective of their infection status. Individuals from all age groups who gave their consent to
participate in the study procedure were enrolled. Urine samples were collected from all individuals and were microscopically examined. Based on the results of the microscopic examination, the participants were divided into the case group positive for *S. haematobium* eggs in urine (SEP) and the negative control group. The control group was further screened to determine total anti-*Schistosoma* IgG antibodies. Based on total IgG results, the control group was divided into two subgroups. The first subgroup contained individuals positive for anti-*Schistosoma* total IgG antibodies and negative for eggs in urine (SELP), and the second subgroup was negative for anti-*Schistosoma* total IgG antibodies and negative for eggs in urine (SELN). This classification is essential in endemic areas in order to differentiate individuals who were potentially resistant from those with a previous or a current infection. Therefore, the detection of anti-*Schistosoma* total IgG was employed as a marker of exposure.

**Sample collection**

Ten ml of urine were collected in a sterile container from all participants and the sample was centrifuged at 5000 rpm for 5 minutes. The supernatant was discarded and the sediment was transferred to a clean glass slide which was microscopically examined for the presence of *S. haematobium* eggs. For negative individuals, urine samples were collected on three successive days in order to confirm that they were true negatives. A Combur-Test reagent strip (Roche Diagnostics GmbH Mannheim, Germany) was used according to the manufacturer’s procedure to estimate the degree of haematuria and proteinuria. About 5 ml of blood sample was collected from all study participants for serological assays and subsequent DNA extraction. Those positive for urinary schistosomiasis were treated with a single dose of 40mg/kg praziquantel. Stool samples were collected from all participants and processed using the Kato-Katz method in order to exclude any individuals with *S. mansoni* infection.

**Serological assays**

Classification of the control group is essential in schistosoma endemic areas, as it is difficult to differentiate individuals without a current infection (either individuals are less susceptible or not been exposed to infection). Therefore detection of anti-schistosoma total IgG was employed as diagnostic exposure marker. Serological assays were carried out to determine the level of anti-*Schistosoma* total IgG antibodies in study participants’ sera by an in-house ELISA assay. In brief: For each individual sample, eight wells were used. The *Schistosoma mansoni* adult antigen was serially diluted from 0.02 to 2.5 μg per 200μl in carbonate buffer (NaHCO₃ + Na₂CO₃ in water, pH = 9.6) and were pre-coated in each well. Negative and positive control plasma samples, were diluted 1:100 with milk buffer. 200μl of the test samples and controls were dispensed into the wells and were incubated for one hour at room temperature. After incubation and subsequent washing steps, each well was treated with 200μl of conjugate solution [goat anti-human IgG bound to alkaline phosphatase, (Sigma-Aldrich, Munich, Germany)] at a concentration of 1:10,000 in 1% milk buffer and incubated for one hour at room temperature. After incubation and subsequent washing steps (5x), 200μl of the substrate [pNPP: 4- Nitrophenyl phosphate disodium salt hexahydrate (Sigma-Aldrich, Munich, Germany)] was added to each well and further incubated for 15 minutes at room temperature. The optical density (OD) was measured at 405 nm. CL-K1 serum levels were determined in all study subjects in 1:5 diluted plasma by a commercially available CL-K1 ELISA kit ELISA kit (EIAab Science, Taiwan) following the manufacturer’s instruction. The lower detection limit of the assay was 7.8 ng/ml.
**COLEC11 genotyping**

Genomic DNA was extracted from blood cells using the QIAamp DNA mini blood kit (Qiagen, Hilden, Germany) according to the manufacturer’s instructions. In a first step, the COLEC11 gene was screened by amplifying the promoter and the eight exons including intron-exon boundaries in 65 healthy individuals. A total of nine genomic fragments of the entire COLEC11 promoter region, including the eight exons were amplified using 10 ng of genomic DNA. The PCR mix consisted of 1x PCR buffer (20 mM Tris-HCl, pH 8.4; 50 mM KCl, 2 mM MgCl2), 0.125 mM of dNTPs, 2 μM of sequence-specific primer pairs and 1 U Taq DNA polymerase (Qiagen, Hilden, Germany). A PTC-200 Thermal cycler (MJ Research, USA) was used. Primer sequences and thermal cycling parameters for the nine PCR reactions are listed in the **S1 Table**. Subsequently, PCR products were purified (Exo-SAP-IT; USB, Affymetrix, USA) and 1 μl of the product was used as template for DNA-sequencing (BigDye terminator v.1.1 cycle sequencing kit, Applied Biosystems, USA) on an ABI 3130XL sequencer. Sequences were aligned with the reference sequence of the COLEC11 gene (NCBI; NG_031954.1) using the CodonCode Aligner 4.0 software (http://www.codoncode.com/) and confirmed visually from their electropherograms.

Based on observed frequencies of ≥ 10% of COLEC11 variants and on variants with recognized functional significance, the variants subjected to further investigation were selected. Four promoter variants (−676T>C, −472T>C, −469C>G, −276C>T), and the non-synonymous (ns) substitution p.R216H in exon8 were genotyped in the entire study group using the primer pairs and PCR conditions as described in **S2 Table**.

**Statistical analysis**

Data were analyzed using the STATA software (STATA Corp., College Station, TX, USA) and the level of significance was set to a p-value of <0.05. Kruskal Wallis rank sum tests following Dunn’s multiple comparison post test were used to analyze the correlation of serum CL-K1 levels with distinct COLEC11 variants using Graphpad Prism v6.0. Fisher’s exact test and logistic regression analyses after adjustment for age and gender were performed to examine associations of CL-K1 variants with schistosomiasis. Correlation analyses were performed by non-parametric Spearman’s rank coefficient tests as implemented in Graphpad Prism v.6.0. Genotype and haplotype frequencies were analyzed by gene counting and expectation-maximum (EM) algorithms and the significance of deviation from Hardy-Weinberg equilibrium was tested using the random-permutation procedure as implemented in the Arlequin v. 3.5.1.2 software (http://lgb.unige.ch/arlequin). Linkage disequilibrium (LD) analysis was performed using Haploview v. 3.2 (http://broadinstitute.org/haploview).

**Results**

**Characteristics of the study groups**

After parasitological and serological tests, our study group was divided into three groups. The case group (SEP) was defined as being positive for *Schistosoma haematobium* eggs in urine [(n = 167), 100(60%) children, 93(55%) males, 74(45%) females and the mean age 17.5 ±13.2]. The first control group is defined as negative for *S. haematobium* eggs in urine but positive for anti-schistosoma total IgG antibodies (SELP) [(n = 119) 22(19%) children, 60(50%) males, 59 (50%) females and the mean age 34.3±19.1] and the second control group defined as negative for *S. haematobium* egg in urine and also negative for anti-schistosoma total IgG antibodies (SELN) [(n = 67), 33(49%) children, 41(61%) males, 26(39%) females and the mean age 20.4 ±17.1]. All of the study subjects belong to the Yoruba ethnicity of the Nigerian population.
The epidemiological data for the case control groups were: Mean age (SEP = 17.5 [4–71], SELP = 34[4–75], SELN = 20[4–71]) and hematuria (SEP = 90%, SELP = 2.4%, SELN = 0%), respectively. The mean parasite count for individuals in the SEP group was 1595 (20–27000) per 10 ml urine.

**COLEC11 gene polymorphisms**

A two step approach was followed to obtain population specific frequencies of COLEC11 variants in the investigated study group. First, the entire promoter region and the eight exons including the intron-exon boundaries were screened in healthy controls (SELN n = 67). The observed frequencies of variants was compared with available HapMap data (S2 Table). The LD plot of observed variants in the entire COLEC11 gene is given in S1 Fig. In the second step, all polymorphisms in the promoter region and the non-synonymous variant p.R216H in exon8 were chosen for further genotyping in the entire study group for investigation of genetic associations with infection phenotype.

**COLEC11 gene polymorphisms and S. haematobium infection risk**

The four gene variants in the promoter region, −676T>C, −472T>C, −469C>G, −276C>T, and the non-synonymous substitution p.R216H in exon8 were genotyped. LDs of the five COLEC11 variants in the case group and the two control subgroups are illustrated in Fig. 1. The promoter variants rs1864480 (−676T/C) and rs4849953 (−472T/C) were observed to be in strong LD in all groups. Genotype and allele frequencies in all groups were in Hardy-Weinberg equilibrium, except for variant rs1864480 (−676T/C) in the egg positive (SEP) cases.

The non-synonymous COLEC11 variant rs7567833G/A (p.R216H) in exon8 was observed more frequently among infected individuals (SEP) than egg and IgG-negative (SELN) healthy controls. The COLEC11 homozygous genotype of the major allele rs7567833-GG was observed significantly more often in the SEP group compared to SELN controls after adjusting for age and gender (OR = 2.35, 95%CI = 1.26–4.37, \( P^{corr} = 0.004 \)), suggesting an association with increased risk of infection. The COLEC11 homozygous genotype of the minor allele rs7567833-AA was observed significantly less often in the SEP group than in the SELN group (OR = 0.2, 95% CI = 0.08–0.90, \( P^{corr} = 0.01 \)), showing an association with decreased risk of urinary schistosomiasis. Similar effects were also observed in the allele distributions (allelic model: OR = 0.44, 95% CI = 0.22–0.72, \( P^{orr} = 0.0004 \); dominant model: OR = 0.42, 95%CI = 0.22–0.79, \( P^{orr} = 0.0048 \); and recessive model: OR = 0.2, 95%CI = 0.08–0.9, \( P^{orr} = 0.01 \)) (Table 1). The observations from the different models indicate a significant contribution of the non-synonymous p.216H substitution as a host genetic factor predisposing to schistosomiasis. Variant p.216H was not observed in linkage with any other COLEC11 variant (Fig. 1). The other investigated COLEC11 variants −472T>C, −469C>G, −276C>T were not associated with urinary schistosomiasis.

The distribution of the reconstructed COLEC11 haplotypes including −472T>C, −469C>G, −276C>T and +48912G>A are summarized in Table 2. Six haplotypes associated with circulating levels of CL-K1 were observed. Among them, COLEC11TCCG, COLEC11CCCCG and COLEC11TCCA were observed at higher frequencies in the entire study group. The COLEC11TCCG haplotype, representing all major alleles, was observed more frequently in cases than in SELN controls (OR = 1.76, 95%CI = 1.15–2.70, \( P^{orr} = 0.007 \)). COLEC11TCCA-p.R216H, was observed more frequently among SELN controls (SEP vs. SELN: OR = 0.38, 95%CI = 0.23–0.63, \( P^{orr} = 0.0001 \); SEP vs. SELP+SELN controls: OR = 0.66, 95%CI = 0.43–0.99, \( P^{orr} = 0.04 \)).
Fig 1. Linkage disequilibrium (LD) pattern of COLEC11 variants in SEP cases group (A), in SELP control group (B), in SELN control group (C) and in SELP+SELN combined control group (D). Open white squares indicate a high degree of LD ($D' = 1$) between pairs of markers. Numbers indicate the $D'$ values.
CL-K1 serum levels and *S. haematobium* infection risk

Mean circulating CL-K1 serum levels among Nigerian individuals without schistosomiasis were 246±155 ng/mL, largely similar to levels observed in Japanese (340±130 ng/mL), Danish (284±180 ng/mL) and American populations (265±177 ng/mL) [25, 26, 35]. The median circulating CL-K1 serum levels in SEP, SELN and SELP+SELN were 161 ng/mL, 206 ng/mL and 175 ng/mL, respectively. Circulating CL-K1 serum levels were heterogeneously distributed between our study subgroups (*P* = 0.0007) (SEP vs. SELN, *P* < 0.001; SEP vs. SELP+SELN, *P* > 0.05) (Fig. 2).

Association of *COLEC11* variants to circulating CL-K1 serum levels

The minor allele of exon8 variant rs7567833A (p.R216H) was significantly associated with increased CL-K1 serum levels (Fig. 3A and Fig. 3B). A gene dose-dependent effect on the distribution of serum CL-K1 levels was observed. Individuals with the COLEC11’TCCA haplotype had higher CL-K1 serum levels in both control groups (SELN: *P* = 0.01 and SELP+SELN: *P* = 0.0004) (Fig. 4), but such a trend was not observed in egg positive (SEP) individuals (S2 Fig). When only COLEC11’TCCA haplotypes were compared among the investigated groups, the SEP group had lower CL-K1 serum levels than the groups (SELP, SELP+SELN) (*P*<0.0001) (Fig. 5). The *COLEC11* haplotypes may further be classified as high expression (*COLEC11’ CCCG + COLEC11’ TCCA*) or as low expression (*COLEC11’ TCGG*) haplotypes based on circulating serum CL-K1 levels observed in the control subgroups (Table 2). The low secretor haplotype (*COLEC11’ TCCG*) was associated

---

Table 1. Distribution of *COLEC11*—rs7567833G/A (p.R216H) genotypes and allele(s).

| Exon8 rs7567833 G/A (p.R216H) | Genotype | SEP* n (%) | SELP+ n (%) | SELN* n (%) | SEP+SELN* n (%) | OR (95% CI) | p* value |
|-------------------------------|----------|------------|-------------|-------------|----------------|-------------|----------|
| **GG**                       | 114 (68.2) | 81 (68)   | 32 (47.8)   | 113 (60.7)  | 2.35 (1.26–4.37) | 0.004      |
| **GA**                       | 46 (27.5) | 37 (31)   | 26 (38.8)   | 63 (33.9)   |               |            |
| **AA**                       | 7 (4.3) | 1 (1)     | 9 (13.4)    | 10 (5.4)    | 0.2 (0.08–0.9) | 0.01       |
| **Allele**                   |          |            |             |             |               |            |
| **G**                        | 274 (82) | 199 (83.6) | 90 (67.2)   | 289 (77.7)  | Reference     |            |
| **A**                        | 60 (18) | 39 (16.4) | 44 (32.8)   | 83 (22.3)   | 0.44 (0.27–0.72) | 0.0008    |
| **Dominant**                 |          |            |             |             | Reference     |            |
| **GG**                       | 114 (68.2) | 81 (68)   | 32 (47.8)   | 113 (60.7)  | Reference     |            |
| **GA+AA**                    | 53 (31.8) | 38 (32)   | 35 (52.2)   | 73 (39.3)   | 0.42 (0.22–0.79) | 0.004     |
| **Recessive**                |          |            |             |             | Reference     |            |
| **GG+GA**                    | 160 (95.7) | 118 (99) | 58 (86.4) | 176 (94.6) | Reference | 0.01 |
| **AA**                       | 7 (4.3) | 1 (1)     | 9 (13.4)    | 10 (5.4)    | 0.2 (0.08–0.9) | 0.01       |

**Note.** CI, confidence interval; OR, odds ratio.

Percentage may not add up to 100 due to rounding errors

* Adjusted *P* values for age and gender

* diagnosed with *S. haematobium* egg in urine [SEP]

* Negative for *S. haematobium* egg in urine but positive for anti-schistosoma total IgG [SELP]

* Negative for *S. haematobium* egg and anti-schistosoma total IgG [SELN]

---

doi:10.1371/journal.pntd.0003647.g001
with *S. haematobium* infection (OR = 1.76, 95%CI = 1.15–2.70, \( P^{corr} = 0.007 \)) and the high secretor haplotypes were associated with decreased risk of infection (OR = 0.52, 95%CI = 0.33–0.79, \( P^{corr} = 0.002 \)).

**Discussion**

Different immune strategies are employed by the host immune system to thwart an infection and the innate immune system plays a critical role in the clearance of some pathogens. Immune evasion from complement components is an important criterion for schistosomes to successfully establish an infection [14,39]. Lectin pathway proteins of the complement system are the first components to recognize the pathogen. These proteins can initiate a complement attack cascade independent of a specific antibody response [40]. Our previous studies have demonstrated that lectin proteins Ficolin-2 [37] and MBL [36] are involved in *S. haematobium* infections.

CL-K1 was first described in 2006 but relatively few studies only have looked at its role in infectious diseases. This study investigated the association between serum CL-K1 level and functional genetic variants in the *COLEC11* gene in urinary schistosomiasis. Our study suggests that a non-synonymous substitution p.R216H in the exon8 of *COLEC11* contributes to susceptibility to schistosomiasis. In particular, the major allele p.R216 increases the infection risk two-fold compared to variant p.216H. Similar effects were also observed in different genetic models for the contribution of the respective p.R216H genotypes. It has been hypothesized that the p.R216H substitution increases the alpha helical propensity value that controls the protein stability and protein folding properties [41]. The p.R216H substitution is located in the carbohydrate recognition domain (CRD) of *COLEC11*, and therefore binding of the CRD with schistosome elements may be impaired. In addition, this particular variant rs7567833G/A (p.R216H) was reported to be under selective pressure [42] and was differentially distributed among a panel of 52 populations as described in HapMap and in the Human Genome Diversity Project–Centre

| **COLEC11** Haplotypes                      | SEP (# n = 334) | SELP (# n = 238) | SELN (# n = 134) | SELP + SELN (# n = 372) | SEP vs SELN OR (95% CI) | \( p^{*} \) value |
|--------------------------------------------|-----------------|------------------|------------------|-------------------------|-------------------------|---------------------|
| *COLEC11*TCCG                             | 184 (55)        | 142 (60)         | 55 (41)          | 197 (53)                | 1.76 (1.15–2.70)        | 0.007               |
| *COLEC11*CCCG                            | 83 (24.9)       | 45 (19)          | 33 (24.6)        | 78 (21)                 | NS                      |                     |
| *COLEC11*TCCA                             | 50 (15)         | 36 (15)          | 42 (31.4)        | 78 (21)                 | 0.38 (0.23–0.63)        | 0.0001              |
| *COLEC11*TGTG                             | 7 (2)           | 12 (5)           | 2 (1.5)          | 14 (3.5)                | NS                      |                     |
| *COLEC11*TGTA                             | 6 (1.8)         | 0 (0)            | 0 (0)            | 0 (0)                   | NS                      |                     |
| *COLEC11*CCCA                             | 4 (1.3)         | 3 (1)            | 2 (1.5)          | 5 (1.5)                 | NS                      |                     |
| **Low Expression**                         |                 |                  |                  |                         |                         |                     |
| *COLEC11*TCCG                             | 184 (55)        | 142 (60)         | 55 (41)          | 197 (53)                | 1.76 (1.15–2.70)        | 0.007               |
| **High Expression**                       |                 |                  |                  |                         |                         |                     |
| *COLEC11*CCCG + *COLEC11*TCCA             | 133 (39.8)      | 81 (34)          | 75 (56)          | 156 (42)                | 0.52 (0.33–0.79)        | 0.002               |

Note. CI, confidence interval; OR, odds ratio.
Percentage may not add up to 100 due to rounding errors
\( a \) Adjusted \( p \) values for age and gender
\( b \) diagnosed with *S. haematobium* egg in urine [SEP]
\( c \) Negative for *S. haematobium* egg in urine but positive for anti-schistosoma total IgG [SELP]
\( d \) Negative for *S. haematobium* egg and anti-schistosoma total IgG [SELN]

doi:10.1371/journal.pntd.0003647.t002
d’Etude du Polymorphisme Humain (HGDP–CEPH) databases [43]. Also, the absence of LD with other genetic variants in proximity indicates selection. None of the promoter polymorphisms contributed to schistosomiasis susceptibility. In addition, the regulatory polymorphisms in the promoter region does not appear to play a role in CL-K1 expression as reported in another study [44].

Fig 2. Distribution of CL-K1 serum levels (median values) among the study groups (SEP: diagnosed with *S. haematobium* egg in urine; SELP: Negative for *S. haematobium* egg in urine but positive for anti-schistosoma total IgG; SELN: Negative for *S. haematobium* egg and anti-schistosoma total IgG). $P = 0.007$ illustrated in the figure is calculated by Kruskal-Wallis rank sum test. Study group comparison were calculated by Dunn’s multiple comparison post test (SEP vs. SELN, $P<0.001$; SEP vs. SELP+SELN, $P>0.05$). Numbers in parentheses indicates absolute counts of sample size in each group.

doi:10.1371/journal.pntd.0003647.g002
Stratification of our study group based on reconstructed COLEC11 haplotypes revealed that the frequency of the COLEC11 ‘TCCG’ haplotype was significantly more frequent in the infection group than in controls, suggesting that individuals with these haplotypes had a higher risk of schistosomiasis. In addition, the COLEC11 ‘TCCA’ haplotype harboring the rs7567833-A polymorphism occurred more frequently in healthy controls compared to the infection group, suggesting that individuals with this haplotype were protected from S. haematobium infection. Furthermore, when the SELP plus SELN controls were analyzed, significant differences were observed with the same haplotype, supporting the suggestion that the COLEC11 ‘TCCA’ haplotype may help confer protection. The frequency of high CL-K1 expressing haplotypes was higher in controls than in SEP cases.

This study demonstrates that CL-K1 serum levels were higher in the control group compared with infected individuals, suggesting that high levels of CL-K1 might reduce the risk of S. haematobium infection. Similar to MBL and ficolins, CL-K1 could recognize and bind to specific glycoproteins on the surface of the pathogen [7,13]. In line with our earlier studies on Ficolin-2 [37] and MBL [36], we believe that CL-K1 serum levels may be down regulated during S. haematobium infection. Recent investigations in patients with disseminated intravascular coagulation (DIC) have shown that CL-K1 levels were significantly elevated [44]. The COLEC11 rs7567833G/A (p.R216H) variant was observed to correlate with increased CL-K1 serum levels. In addition, the COLEC11 ‘TCCA’ haplotype with the allele p.R216 was associated with higher CL-K1 serum levels in healthy individuals. Inversely, COLEC11 ‘TCCG’ with allele p.R216 was associated with lower CL-K1 serum levels. These results substantiate that the variant in exon8 is a host genetic factor that may help protect against schistosomiasis. When the individuals with COLEC11 ‘TCCA’ were analyzed for CL-K1 serum levels in the different patient
Fig 4. Distribution of CL-K1 serum levels (median values) with investigated COLEC11 haplotypes (Left) SELN controls (Right): SELP+SELN combined controls. \( P = 0.03 \) and \( P = 0.0004 \) illustrated in the figures are calculated by Kruskal-Wallis rank sum test. Study group comparison were calculated by Dunn’s multiple comparison post test (COLEC11*TCCG-SELN vs. COLEC11*TCCA-SELN, \( P < 0.05 \); COLEC11*CCCG-SELN vs. COLEC11*TCCA-SELN, \( P = 0.05 \); COLEC11*TCCG-SELN+SELP vs. COLEC11*TCCA-SELN+SELP, \( P = 0.001 \); COLEC11*TCCG-SELN+SELP vs. COLEC11*CCCG-SELN+SELP, \( P = 0.05 \)). Numbers in parentheses indicate absolute counts of sample size in each group. SEP: diagnosed with S. haematobium egg in urine; SELP: Negative for S. haematobium egg in urine but positive for anti-schistosoma total IgG; SELN: Negative for S. haematobium egg and anti-schistosoma total IgG.

doi:10.1371/journal.pntd.0003647.g004

Fig 5. Distribution of CL-K1 serum levels (median values) with investigated COLEC11*TCCA haplotype in all study groups. \( P < 0.0001 \) illustrated in the figure is calculated by Kruskal-Wallis rank sum test. Study group comparison were calculated by Dunn’s multiple comparison post test (COLEC11*TCCA-SEP vs. COLEC11*TCCA–SELN, \( P < 0.001 \); COLEC11*TCCA–SEP vs. COLEC11*TCCA–SELP+SELN, \( P < 0.01 \)). Numbers in parentheses indicates absolute counts of sample size in each group. SEP: diagnosed with S. haematobium egg in urine; SELP: Negative for S. haematobium egg in urine but positive for anti-schistosoma total IgG; SELN: Negative for S. haematobium egg and anti-schistosoma total IgG.

doi:10.1371/journal.pntd.0003647.g005
groups, SEP individuals had lower levels than egg negatives, indicating that CL-K1 serum levels were modulated by infection.

CL-K1 has a collagen and a ligand binding domains, similar to MBL and ficolins. These structural domains bind specifically to pathogen-associated molecular patterns (PAMPs) on the surface of infectious agents [45]. We postulate that CL-K1, along with the MBL-associated serine proteases MASP-1/3 and MASP-2 initiate the complement lectin cascade to reduce S. haematobium infection. [20,30,34].

We have shown that allelic variants associated with increased CL-K1 levels may be a contributing protective host factor in schistosomiasis caused by S. haematobium. Furthermore, the variant in p.R216H in exon8 of the COLEC11 gene is a host genetic factor associated with urinary schistosomiasis. Taken together, both COLEC11 variants and CL-K1 serum levels are associated with the phenotype occurring after S. haematobium infection.

Supporting Information
S1 Checklist. STROBE checklist.

S1 Table. Primer pairs and PCR program conditions utilized for screening the COLLEC11 gene.

S2 Table. Distribution of screened COLEC11 variants in SELN Controls and its comparison with HapMap data of Yoruba ethnicity.

S1 Fig. Linkage disequilibrium pattern of screened COLEC11 variants in SELN control group. Open white squares indicate a high degree of LD (D' = 1) between pairs of markers. Numbers indicate the D' value expressed as a percentile. The red square indicates pairs in strong LD with LOD scores ≥ 2; purple squares, D' = 1 with LOD scores ≤ 1. A solid line outlines the haplotype block.

S2 Fig. Distribution of CL-K1 serum levels (median values) with investigated COLEC11 haplotypes in SEP cases (SEP: diagnosed with S. haematobium egg in urine). P = 0.8 value illustrated in the figure is calculated by Kruskal-Wallis rank sum test. Numbers in parentheses indicates absolute counts of sample size in each group.

Acknowledgments
We thank Abass Busari of State Hospital Ijaye, Abeokuta, Sanusi Tawakalitu, Olaolu Abdula-zeez and Adedokun Samuel of Ladoke Akintola University of Technology, Osogbo for the technical support. We extend our thanks to Akeem Akindele, Olawumi Sina-Agbaje and Adegboyega Adeyeba for their extensive help during sampling. We also thank all the staff of Schistosomiasis control unit, Ministry of Health, Abeokuta, and the community members for their participation in the study. We thank Prabhanjan Gai for help with sequencing.
Author Contributions
Conceived and designed the experiments: TPV JSA. Performed the experiments: JSA. Analyzed the data: JSA TPV. Contributed reagents/materials/analysis tools: TPV PGK OO. Wrote the paper: TPV JSA OO.

References
1. Steinmann P, Keiser J, Bos R, Tanner M, Utzinger J (2006) Schistosomiasis and water resources development: systematic review, meta-analysis, and estimates of people at risk. The Lancet infectious diseases 2006/06/23: 411–425. Meta-Analysis Research Support, Non-U.S. Gov't Review.
2. Hotez PJ, Fenwick A, Kjetland EF (2009) Africa's 32 cents solution for HIV/AIDS. PLoS neglected tropical diseases 2009/05/30: e430. Editorial.
3. King CH (2010) Parasites and poverty: the case of schistosomiasis. Acta tropica 2009/12/08: 95–104. Research Support, N.I.H., Extramural Review.
4. King CH, Dickman K, Tisch DJ (2005) Reassessment of the cost of chronic helminthic infection: a meta-analysis of disability-related outcomes in endemic schistosomiasis. Lancet 2005/05/04: 1561–1569. Meta-Analysis Research Support, U.S. Gov't, P.H.S.
5. King CH, Dangerfield-Cha M (2008) The unacknowledged impact of chronic schistosomiasis. Chronic illness 2008/03/07: 65–79. Research Support, N.I.H., Extramural Review.
6. Ekpo UF, Laja-Deile A, Oluwole AS, Sam-Wobo SO, Maflana CF (2010) Urinary schistosomiasis among preschool children in a rural community near Abeokuta, Nigeria. Parasit Vectors 3: 58. doi: 10.1186/1756-3305-3-58 PMID: 20602792
7. Hotez PJ, Asojo OA, Adesina AM (2012) Nigeria: “Ground Zero” for the high prevalence neglected tropical diseases. PLoS neglected tropical diseases 2012/08/04: e1600. Editorial.
8. Bamgbola OF (2014) Urinary schistosomiasis. Pediatric nephrology 2014/01/29.
9. Botelho MC, Machado JC, Brindley PJ, Correia da Costa JM (2011) Targeting molecular signaling pathways of Schistosoma haemotobium infection in bladder cancer. Virulence 2011/07/27: 267–279. Review.
10. van der Werf MJ, de Vlas SJ, Brooker S, Looman CW, Nagelkerke NJ, Engels D, Looman CW, Nagelkerke NJ, Engels D (2003) Quantification of clinical morbidity associated with schistosome infection in sub-Saharan Africa. Acta tropica 2003/05/15: 125–139. Research Support, Non-U.S. Gov't.
11. Stothard JR, Sousa-Figueiredo JC, Betson M, Bustinduy A, Reinhard-Rupp J (2013) Schistosomiasis in African infants and preschool children: let them now be treated! Trends in parasitology 2013/03/08: 197–205. Research Support, Non-U.S. Gov't Review.
12. Yazdanbakhsh M, Sacks DL (2010) Why does immunity to parasites take so long to develop? Nature reviews Immunology 2010/02/26: 80–81.
13. Ross AG, Bartley PB, Sleigh AC, Olds GR, Li Y, Williams GM, McManus DP (2002) Schistosomiasis. The New England journal of medicine 2002/04/19: 1212–1220. Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S. Review.
14. Skelly PJ, Alan Wilson R (2006) Making sense of the schistosome surface. Advances in parasitology 2006/12/01: 185–284. Review.
15. Peterson NA, Hokke CH, Deelder AM, Yoshino TP (2009) Glycotope analysis in miracidia and primary sporocysts of Schistosoma mansoni: differential expression during the miracidium-to-sporocyst transformation. International journal for parasitology 2009/06/24: 1331–1344. Research Support, N.I.H., Extramural.
16. Hayunga EG, Sumner MP (1986) Expression of lectin-binding surface glycoproteins during the development of Schistosoma mansoni schistosomula. The Journal of parasitology 1986/12/01: 913–920. Research Support, U.S. Gov't, P.H.S.
17. Meevissen MH, Yazdanbakhsh M, Hokke CH (2012) Schistosoma mansoni egg glycoproteins and C-type lectins of host immune cells: molecular partners that shape immune responses. Experimental parasitology 2011/05/28: 14–21. Review.
18. Rasmussen KR, Kemp WM (1987) Schistosoma mansoni: interactions of adult parasites with the complement system. Parasite immunology 1987/03/01: 235–248. Research Support, Non-U.S. Gov't.
19. Klabunde J, Berger J, Jensenius JC, Klinkert MQ, Zeick UE, Kremsner PG, Kun JF (2000) Schistosoma mansoni: adhesion of mannann-binding lectin to surface glycoproteins of cercariae and adult worms. Experimental parasitology 2000/10/20: 231–239. Research Support, Non-U.S. Gov't.
20. Keshi H, Sakamoto T, Kawai T, Ohtani K, Katoh T, Jang SJ, Motomura W, Yoshizaki T, Fukuda M, Koyama S, Fukuzawa J, Fukuh A, Yoshida I, Suzuki Y, Wakamiya N (2006) Identification and characterization of a novel human collectin CL-K1. Microbiology and immunology 2006/12/21: 1001–1013. Research Support, Non-U.S. Gov't.

21. Bouwman LH, Roep BO, Roos A (2006) Mannose-binding lectin: clinical implications for infection, transplantation, and autoimmunity. Human immunology 2006/05/25: 247–256. Review.

22. Goedelner I, Skare TL, Utyayma SR, Nishiara RM, Tong H, Messias-Reason IU, Velavan TP (2014) Mannose binding lectin and susceptibility to rheumatoid arthritis in Brazilian patients and their relatives. PLoS One 9: e95519. doi: 10.1371/journal.pone.0095519 PMID: 24751721

23. Jha AN, Sundaravadivel P, Singh VK, Pati SS, Patra PK, Kremsner PG, Velavan TP, Singh L, Thangaraj K (2014) MBL2 variations and malaria susceptibility in Indian populations. Infect Immun 82: 52–61. doi: 10.1128/IAI.01041-13 PMID: 24126531

24. Velavan TP, Boldt AB, Tomiuk J, Seibold F, Schoepfer AM, Flogerzi B, Muller S, Abad-Grau MM, Kremsner PG, Kun JF (2010) Variant alleles of the mannos binding lectin 2 gene (MBL2) confer heterozygote advantage within Crohn's families. Scand J Gastroenterol 45: 1129–1130. doi: 10.3109/00365551.2010.485324 PMID: 20443743

25. Ren Y, Ding Q, Zhang X (2014) Ficolins and infectious diseases. Virologica Sinica 2014/01/24: 25–32.

26. Assaf A, Hoang TV, Faik I, Aebischer T, Kremsner PG, Kun JF, Velavan TP (2012) Genetic evidence of functional ficolin-2 haplotype as susceptibility factor in cutaneous leishmaniasis. PLoS One 7: e34113. doi: 10.1371/journal.pone.0034113 PMID: 22457818

27. Hoang TV, Toan NL, Song IH, Ouf EA, Bock CT, Kremsner PG, Kun JF, Velavan TP (2011) Ficolin-2 levels and FCN2 genetic polymorphisms as a susceptibility factor in cutaneous leishmaniasis. Virologica Sinica 2011/03/02: 1675–1683. Research Support, Non-U.S. Gov't.

28. Luz PR, Boldt AB, Grisbach C, Kun JF, Velavan TP, Messias-Reason IJ (2013) Association of L-ficolin levels and FCN2 genotypes with chronic Chagas disease. PLoS One 8: e60237. doi: 10.1371/journal.pone.0060237 PMID: 23593180

29. Ohtani K, Suzuki Y, Wakamiya N (2012) Biological functions of the novel collectins CL-L1, CL-K1, and CL-P1. Journal of biomedicine & biotechnology 2012/05/10: 493945. Research Support, Non-U.S. Gov't Review.

30. Hansen S, Selman L, Palaniyar N, Ziegler K, Hartshorn K, Jorgensen TJ, Skjodt K, Holmskov U (2010) Collectin 11 (CL-11, CL-K1) is a MASP-1/3-associated plasma collectin with microbial-binding activity. Journal of immunology 2010/10/20: 6096–6104. Research Support, Non-U.S. Gov't.

31. Motomura W, Yoshizaki T, Ohtani K, Suzuki Y, Kohgo Y, Wakamiya N (2008) Immunolocalization of a novel collectin CL-K1 in murine tissues. The journal of histochemistry and cytochemistry: official journal of the Histochemistry Society 2007/11/28: 243–252. Research Support, Non-U.S. Gov't.

32. Henriksen ML, Brandt J, Andrieu JP, Nielsen C, Jensen PH, Holmskov U, Jorgensen TJ, Palarasah Y, Thielemans NM, Hansen S (2013) Heteromeric complexes of native collectin kidney 1 and collectin liver 1 are found in the circulation with MASPs and activate the complement system. Journal of immunology 2013/11/01: 6117–6127. Research Support, Non-U.S. Gov't.

33. Chang JC, Kuo HC, Hsu TY, Ou CY, Liu CA, Chuang H, Liang HM, Huang HW, Yang KD (2013) Different genetic associations of the IgE production among fetus, infancy and childhood. PloS one 2013/08/13: e70362. Comparative Study Research Support, Non-U.S. Gov't.

34. Henriksen ML, Brandt J, Andrieu JP, Nielsen C, Jensen PH, Holmskov U, Jorgensen TJ, Palarasah Y, Thielemans NM, Hansen S (2013) Heteromeric complexes of native collectin kidney 1 and collectin liver 1 are found in the circulation with MASPs and activate the complement system. Journal of immunology 2013/11/01: 6117–6127. Research Support, Non-U.S. Gov't.

35. Selman L, Hansen S (2012) Structure and function of collectin liver 1 (CL-L1) and collectin 11 (CL-11, CL-K1). Immunobiology 2012/04/06: 851–863. Research Support, Non-U.S. Gov't Review.

36. Antony JS, Ojurongbe O, van Tong H, Ouf EA, Engleitner T, Akindele AA, Sina-Agbaje OR, Adeyeba AO, Kremsner PG, Velavan TP (2013) Mannose-binding lectin and susceptibility to schistosomiasis. The Journal of infectious diseases 2013/03/02: 1675–1683. Research Support, Non-U.S. Gov't.

37. Ouf EA, Ojurongbe O, Akindele AA, Sina-Agbaje OR, van Tong H, Adeyeba AO, Kremsner PG, Kun JF, Velavan T (2012) Ficolin-2 levels and FCN2 genetic polymorphisms as a susceptibility factor in schistosomiasis. The Journal of infectious diseases 2012/06/14: 562–570. Research Support, Non-U.S. Gov't.

38. Ojurongbe O, Sina-Agbaje OR, Busari A, Okorie PN, Ojurongbe TA, Akindele AA (2014) Efficacy of praziquantel in the treatment of Schistosoma haematobium infection among school-age children in...
rural communities of Abeokuta, Nigeria. Infect Dis Poverty 3: 30. doi: 10.1186/2049-9957-3-30 PMID: 25215186

39. Deng J, Gold D, LoVerde PT, Fishelson Z (2003) Inhibition of the complement membrane attack complex by Schistosoma mansoni paramyosin. Infection and immunity 2003/10/24: 6402–6410. Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.

40. Cestari I, Evans-Osses I, Schlapbach LJ, de Messias-Reason I, Ramirez MI (2013) Mechanisms of complement lectin pathway activation and resistance by trypanosomatid parasites. Molecular immunology 2012/10/16: 328–334. Research Support, Non-U.S. Gov't Review.

41. Pace CN, Scholtz JM (1998) A helix propensity scale based on experimental studies of peptides and proteins. Biophys J 75: 422–427. PMID: 9649402

42. International HapMap C (2005) A haplotype map of the human genome. Nature 2005/10/29: 1299–1320. Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.

43. Xue Y, Zhang X, Huang N, Daly A, Gillson CJ, Macarthur DG, Yngvadottir B, Nica AC, Woodwark C, Chen Y, Conrad DF, Ayub Q, Mehdi SQ, Li P, Tyler-Smith C (2009) Population differentiation as an indicator of recent positive selection in humans: an empirical evaluation. Genetics 2009/09/10: 1065–1077. Research Support, Non-U.S. Gov't.

44. Takahashi K, Ohtani K, Larvie M, Moyo P, Chigweshe L, Van Cott EM, Wakamiya N (2014) Elevated plasma CL-K1 level is associated with a risk of developing disseminated intravascular coagulation (DIC). Journal of thrombosis and thrombolysis 2014/01/30.

45. Degn SE, Jensenius JC, Thiel S (2011) Disease-causing mutations in genes of the complement system. American journal of human genetics 2011/06/15: 689–705. Research Support, Non-U.S. Gov't Review.